22
total announcements
AJANTPHARM.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 15 Oct 2026
Market Cap
₹41,224 Cr
P/E (TTM)
36.3
P/E (Forward)
28.3
EPS (TTM)
₹90.79
52W Low
₹2,382.00
52W High
₹3,796.00
Dividend Yield
1.92%
Beta
0.22
Price / Book
9.1
Debt / Equity
5.9
Revenue (TTM)
₹5,776 Cr
Gross Margin
77.22%
Operating Margin
25.20%
Ajanta Pharma Limited
Ajanta Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018.
Ajanta Pharma Limited
Ajanta Pharma Limited has submitted its Sustainability Report for FY 2025-26, highlighting its environmental, social, and governance (ESG) initiatives and progress.
Ajanta Pharma Limited
Ajanta Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Ajanta Pharma Limited
Ajanta Pharma Limited has informed the Exchange about the schedule of Analyst/Institutional Investor Meeting with the Company.
Ajanta Pharma Limited
Ajanta Pharma Limited has informed the Exchange about a newspaper publication regarding the transfer of unclaimed dividends to the Investor Education and Protection Fund (IEPF) and a job advertisement for the University of Delhi.
Ajanta Pharma Limited
Ajanta Pharma Limited has informed the Exchange about its participation in two investor conferences: Nuvama India Conference 2026 and Motilal Annual Global Conference. The company has confirmed that the discussions during these meetings will be based on already published information.
Ajanta Pharma Limited
Ajanta Pharma Limited has uploaded the written transcript of its earnings call held on 30th July 2026 on its website, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
Ajanta Pharma Limited
Ajanta Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding unaudited financial results for the quarter ended June 30, 2026.
Ajanta Pharma Limited
Ajanta Pharma Limited has uploaded the audio recording of its earnings call held on 30th July 2026 on its website.
Ajanta Pharma Limited
Ajanta Pharma Limited has informed the Exchange about ESOP Allotment, where the Nomination & Remuneration Committee of the Board has allotted 23,400 fully paid-up equity shares of Rs. 2/- each issued upon exercise of options, increasing the paid-up capital of the Company to Rs. 24,99,18,048.
Ajanta Pharma Limited
Ajanta Pharma Limited has declared a select dividend of Rs. 32 per equity share, with a record date of July 30, 2026, and payment date of August 18, 2026. The company's unaudited consolidated and standalone financial results for the first quarter ended June 30, 2026, show a revenue increase of 25% and profit after tax (PAT) increase of 31%. The company has also announced its intention to pay an interim dividend of Rs. 32 per share, amounting to Rs. 400 cr.
Ajanta Pharma Limited
Ajanta Pharma Limited has announced a record date for the purpose of determining shareholders eligible for the 1st interim dividend, set for August 5, 2026.
Ajanta Pharma Limited
Ajanta Pharma Limited has announced its Q1 FY 2027 financial results, with revenue up 25% and PAT up 31% compared to Q1 FY 2026. The company has also approved an interim dividend of Rs. 32 per share, amounting to Rs. 400 cr. The company's India branded generic segment has exceeded IPM growth by 36%, driven by new launches and volumes.
Ajanta Pharma Limited
Ajanta Pharma Limited
Ajanta Pharma Limited has announced the schedule of its Earnings Conference Call to be held on 30th July 2026, post Board meeting, to discuss Q1 FY 2027 Unaudited Financial Results.
Ajanta Pharma Limited
Ajanta Pharma Limited has submitted the Exchange a copy Scrutinizer's report of Annual General Meeting held on July 16, 2026, and informed the Exchange regarding voting results.
Ajanta Pharma Limited
Ajanta Pharma Limited held its 47th Annual General Meeting on July 16, 2026, through video-conference, with all directors and statutory auditors present. The meeting approved the consolidated and standalone financial statements for the year ended March 31, 2026, and confirmed the interim dividend as final dividend. The company also re-appointed Mr. Mannalal B. Agrawal as a director and ratified the remuneration of the cost auditors.
Ajanta Pharma Limited
Ajanta Pharma Limited has received a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the acceptance or rejection of securities for dematerialization and listing on stock exchanges.
Ajanta Pharma Limited
Ajanta Pharma Limited has received the Establishment Inspection Report (EIR) from the US FDA for its Paithan manufacturing facility, which has been classified as Voluntary Action Indicated (VAI) following a cGMP inspection.
Ajanta Pharma Limited
Ajanta Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.